Δ9-Tetrahydrocannabinol reverses TNFα-induced increase in airway epithelial cell permeability through CB2 receptors

Biochemical Pharmacology

Volumn 120, Issue , 2016, Pages 63-71

  Shang, Valerie C M ^a   Kendall, David A ^a   Roberts, Richard E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Airway; Cannabinoid receptors; Epithelium; THC; Tight junctions

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DRONABINOL; INTERLEUKIN 1BETA; OCCLUDIN; PROTEIN ZO1; TUMOR NECROSIS FACTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CNR2 PROTEIN, HUMAN; IL1B PROTEIN, HUMAN; LIGAND; NONSTEROID ANTIINFLAMMATORY AGENT; OCLN PROTEIN, HUMAN; PSYCHEDELIC AGENT; TIGHT JUNCTION PROTEIN; TJP1 PROTEIN, HUMAN; TNF PROTEIN, HUMAN;

AIRWAY EPITHELIAL CELL; ARTICLE; CELL CULTURE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; AGONISTS; ALGORITHM; ANTAGONISTS AND INHIBITORS; BRONCHUS; DRUG EFFECTS; IMMUNOLOGY; IMPEDANCE; KINETICS; METABOLISM; PERMEABILITY; RESPIRATORY MUCOSA; TIGHT JUNCTION; TUMOR CELL LINE;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRONCHI; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; DRONABINOL; ELECTRIC IMPEDANCE; HALLUCINOGENS; HUMANS; INTERLEUKIN-1BETA; KINETICS; LIGANDS; OCCLUDIN; PERMEABILITY; RECEPTOR, CANNABINOID, CB2; RESPIRATORY MUCOSA; TIGHT JUNCTION PROTEINS; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84992549055     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.09.008     Document Type: Article

References (28)

1. [1] Holgate, S.T., The sentinel role of the airway epithelium in asthma pathogenesis. Immunol. Rev. 242 (2011), 205–219.
2. [2] Schneeberger, E.E., Lynch, R.D., The tight junction: a multifunctional complex. Am. J. Physiol. 286 (2004), C1213–C1228.
3. [3] Bousquet, J., Jeffery, P.K., Busse, W.W., Johnson, M., Vignola, A.M., Asthma – from bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 161 (2000), 1720–1745.
4. [4] Hardyman, M.A., Wilkinson, E., Martin, E., Jayasekera, N.P., Blume, C., Swindle, E.J., Gozzard, N., Holgate, S.T., Howarth, P.H., Davies, D.E., Collins, J.E., TNF-alpha-mediated bronchial barrier disruption and regulation by src-family kinase activation. J. Allergy Clin. Immunol. 132 (2003), 665–675.
5. [5] Nuijsink, M., Hop, W.C.J., Sterk, P.J., Duiverman, E.J., De Jorgste, J.C., Grp, C.S., Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial. Eur. Respir. J. 30 (2007), 457–466.
6. [6] Xiao, C., Puddicombe, S.M., Field, S., Haywood, J., Broughton-Head, V., Puxeddu, I., Haitchi, H.M., Vernon-Wilson, E., Sammut, D., Bedke, N., Cremin, C., Sones, J., Djukanović, R., Howarth, P.H., Collins, J.E., Holgate, S.T., Monk, P., Davies, D.E., Defective epithelial barrier function in asthma. J. Allergy Clin. Immunol. 128 (2011), 549–556.
7. 2 receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. Br. J. Pharmacol. 153 (2008), 199–215.
8. [8] Makwana, R., Venkatasamy, R., Spina, D., Page, C., The effect of phytocannabinoids on airway hyper-responsiveness, airway inflammation, and cough. J. Pharmacol. Exp. Ther. 353 (2015), 169–180.
9. [9] Giannini, L., Nistri, S., Mastroianni, R., Cinci, L., Vannacci, A., Mariottini, C., Passani, M.B., Mannaioni, P.F., Bani, D., Masini, E., Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs. J. Cell Mol. Med. 12 (2008), 2381–2394.
10. [10] Stengel, P.W., Cockerham, S.L., Silbaugh, S.A., Inhaled anandamide reduces leukotriene D-4-induced airway obstruction in guinea pigs. Eur. J. Pharmacol. 557 (2007), 66–68.
11. [11] Alhamoruni, A., Wright, K.L., Larvin, M., O'Sullivan, S.E., Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br. J. Pharmacol. 165 (2012), 2598–2610.
12. [12] Alhamoruni, A., Lee, A.C., Wright, K.L., Larvin, M., O'Sullivan, S.E., Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J. Pharmacol. Exp. Ther. 335 (2010), 92–102.
13. [13] Rinaldi-Carmona, M., Barth, F., Millan, J., Deroco, J., Casella, P., Congy, C., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., Brelière, J.C., Le Fur, G.L., SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284 (1998), 644–650.
14. [14] Wan, H., Winton, H.L., Soeller, C., Stewart, G.A., Thompson, P.J., Gruenert, D.C., Cannell, M.B., Garrod, D.R., Robinson, C., Eur. Respir. J. 15 (2000), 1058–1068.
15. [15] Tashkin, D.P., Reiss, S., Shapiro, B.J., Calvarese, B., Olsen, J.L., Lodge, J.W., Bronchial effects of aerosolized Δ-9-tetrahydrocannabinol in healthy and asthmatic subjects. Am. Rev. Respir. Dis. 115 (1977), 57–65.
16. [16] Sousa, A.R., Lane, S.J., Nakhosteen, J.A., Lee, T.H., Poston, R.N., Expression of interleukin-1 beta (IL-1 β) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. Am. J. Respir. Crit. Care Med. 154 (1996), 1061–1066.
17. [17] Culpitt, S.V., Rogers, D.F., Shah, P., De Matos, C., Russell, R.E.K., Donnelly, L.E., Barnes, P.J., Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 167 (2003), 24–31.
18. [18] Mickleborough, T.D., Lindlet, M.R., Ray, S., Dietary salt, airway inflammation, and diffusion capacity in exercise-induced asthma. Med. Sci. Sports Exerc. 37 (2005), 904–914.
19. [19] Foster, K.A., Avery, M.L., Yazdanian, M., Audus, K.L., Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int. J. Pharm. 208 (2000), 1–11.
20. [20] Mathias, N.R., Timoszyk, J., Stetsko, P.I., Megill, J.R., Smith, R.L., Wall, D.A., Permeability characteristics of Calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats. J. Drug Target. 10 (2002), 31–40.
21. [21] Vllasaliu, D., Flower, R., Garnett, M., Eaton, M., Stolnik, S., Barrier characteristics of epithelial cultures modelling the airway and intestinal mucosa: a comparison. Biochem. Biophys. Res. Commun. 415 (2001), 579–585.
22. 123I-labelled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol. 307 (1996), 331–338.
23. [23] R.G. Pertwee, A.C. Howlett, M. Abood, F. Barth, T.I. Bonner, G. Cabral, et al., Cannabinoid receptors. IUPHAR/BPS Guide to Pharmacology, http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=13, 2010.
24. [24] Huffman, J.W., Liddle, J., Yu, S., Aung, M.M., Abood, M.E., Wiley, J.L., Martin, B.R., 3-(1',1'-Dimethylbutyl)-1-deoxy-Delta(8)-THC and related compounds: Synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem. 7 (1999), 2905–2914.
25. [25] Hillard, C.J., Manna, S., Greenberg, M.J., Dicamelli, R., Ross, R.A., Stevenson, L.A., Murphy, V., Pertwee, R.G., Campbell, W.B., Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 289 (1999), 1427–1433.
26. [26] Gkoumassi, E., Dekkers, B.G.J., Droge, M.J., Elzinga, C.R.S., Schmidt, M., Meurs, H., Zaagsma, J., Nelemans, S.A., Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells. Br. J. Pharmacol. 151 (2007), 1041–1048.
27. [27] Wan, H., Winton, H.L., Soeller, C., Stewart, G.A., Thompson, P.J., Gruenert, D.C., Cannell, M.B., Garrod, D.R., Robinson, C., Tight junction properties of the immortalized human bronchial epithelial cell lines Calu-3 and 16HBE14o. Eur. Respir. J. 15 (2000), 1058–1068.
28. [28] Coyne, C.B., Vanhook, M.K., Gambling, T.M., Carson, J.L., Boucher, R.C., Johnson, L.G., Regulation of airway tight junctions by proinflammatory cytokines. Mol. Biol. Cell 13 (2002), 3218–3234.